A lot of effort has been focused on targeting prostate cancer cell markers, such as the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR), to improve diagnosis and therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.